In product development, intellectual property is often discussed relatively late.
The conversation tends to begin when an invention is ready to be protected, a filing strategy is taking shape, or external investors start asking how the company plans to defend its position. By that stage, the focus is often on what can be patented and how broadly protection can be built.
That is important, but it is only part of the picture.
For many companies, especially in MedTech and HealthTech, the more immediate question is not only what can be protected. It is whether the planned product can be developed, positioned, and commercialised with a clear understanding of the existing patent landscape.
This is where Freedom to Operate, or FTO, becomes highly relevant.
Looking beyond patentability
Patentability and Freedom to Operate are often discussed together, but they answer different questions.
Patentability focuses on whether an invention appears new and inventive enough to support patent protection. Freedom to Operate focuses on whether a planned product or solution may conflict with active third-party rights in the markets where the company intends to operate. In practical terms, FTO is about reducing the risk of investing heavily in a direction that later proves difficult to commercialise.
This distinction matters because owning a patent does not automatically mean a company is free to use, manufacture, or sell its product. In dense technology areas, especially those involving devices, software, methods, or integrated systems, relevant third-party patents may still create constraints.
Why FTO matters early
FTO is often associated with a final legal review before launch. In practice, it is most valuable much earlier.
When considered at the right stage, it can help guide development decisions before significant resources are committed. It can show where the patent landscape is crowded, where design choices may create avoidable risk, and where there may be more room to operate. It can also support decisions about market focus, product scope, and possible design-around strategies.
For this reason, FTO should not be treated only as a last-stage legal checkpoint. It is also a strategic development tool.
In medical technology, this is particularly important. Products often combine multiple technical elements, and the patent environment may include device claims, method-related claims, software-related claims, and system-level claims that affect commercial freedom in different ways.
Patent strategy is not only about filing more
A strong patent strategy is not built only by increasing the number of filings.
It is built by making better decisions about where to focus innovation, how to position it, and how to protect commercially meaningful aspects of the solution. That requires an understanding of both the company’s own technology and the surrounding landscape.
This is one of the reasons FTO and patent strategy are closely connected. FTO helps identify constraints, but it can also reveal opportunities. It may highlight less crowded technical directions, potential white space, or areas where the company’s own patenting efforts can be more targeted and defensible.
When handled well, patent strategy becomes more than a filing exercise. It becomes part of broader decision-making around product development and market access.
A practical question, not only a legal one
In many companies, IP work is still separated from development decisions for too long.
That separation can create inefficiencies. Teams may move forward with technical solutions that are difficult to protect, difficult to commercialise, or unnecessarily exposed to third-party rights. By contrast, when FTO and patent strategy are considered earlier, they can support a more informed development path.
This does not mean every early-stage product requires exhaustive legal analysis from the outset. It means that IP should be approached in a structured and proportionate way, with enough visibility to support practical decision-making before risks become expensive.
For growing companies, this is often where the greatest value lies.
Supporting better decisions from the start
For MedTech and HealthTech companies, IP strategy works best when it is connected to the realities of development, regulatory planning, and market use.
That is why FTO and patent strategy are often most useful when they are not treated as isolated legal activities, but as part of a broader product and business strategy. Understanding the patent environment early can help teams prioritise more effectively, reduce avoidable risk, and build stronger long-term positioning.
At MDS, this work is approached with that broader perspective in mind. The goal is not only to support filing decisions, but to help companies understand where they can move with confidence and how their innovation can be positioned more strategically in the market. This is also how MDS presents its IPR offering, with emphasis on FTO, landscape analysis, and strategic patent support for commercially valuable portfolios.
Looking ahead
As technology areas become more interconnected, the role of IP in product development continues to expand.
For many companies, the key question is no longer only how to protect an invention once it is ready. It is how to make stronger decisions while it is still taking shape.
Freedom to Operate is an important part of that process. Not because it removes all uncertainty, but because it helps companies move forward with a clearer view of the risks, options, and opportunities ahead.
If your team is assessing product direction, planning market entry, or shaping a stronger patent position, MDS supports companies with practical Freedom to Operate analysis and patent strategy aligned with real development and commercial goals.
You can contact us at Kristian@mdsdenmark.dk or via Book a Meeting.